Zusammenfassung
Der Wissenszuwachs im Bereich von Tumorbiologie, Früherkennung, Diagnostik und Therapie des Mammakarzinoms ist rasant. Eine regelmäßige Erneuerung der Leitlinie ist aus diesem Grund unabdingbar. Durch intensive Arbeit aller beteiligten Institutionen konnten überarbeitete und ergänzte Behandlungsempfehlungen im Rahmen der aktualisierten S3-Leitlinie ausgesprochen werden. Grundlage des Aktualisierungsprozesses war ein methodisch definiertes S3(Stufe 3)-Regelwerk des Leitlinienprogrammes Onkologie (OL) der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), der Deutschen Krebsgesellschaft und der Deutschen Krebshilfe. Die Härte der Empfehlungsgrade richtet sich dabei nach der Belastbarkeit der Evidenz und der klinischen Relevanz (soll – sollte – kann).
Abstract
The gain in knowledge in the field of tumor biology, screening, diagnostics and therapy of breast cancer is rapid. Thus, a regular renewal of the guidelines is absolutely necessary. Through intensive work of all participating institutions it was possible to create revised and supplementary treatment recommendations within the framework of the updated S3 guidelines. The foundation of the updating process was a methodically defined S3 algorithm of the guideline program oncology of the Association of the Scientific Medical Societies in Germany (AWMF), the German Cancer Society and German Cancer Aid (Krebshilfe). The strength of the recommendation grade is based on the weight of the evidence and the clinical relevance (must-should-can).
This is a preview of subscription content, log in via an institution to check access.
Literatur
Caumo F et al (2014) Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. Breast 23(1):76–80
Lang K et al (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmo Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 26(1):184–190
Skaane P et al (2014) Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271(3):655–663
Hahnen E et al (2017) Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. Jama Oncol 3(10):1378–1385
Liu M et al (2013) Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett 5(3):983–991
Moran MS et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32(14):1507–1515
Lyman GH, Somerfield MR, Giuliano AE (2017) Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract 13(3):196–198
McCormick B et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709–715
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology : official journal of the European Society for Medical. Oncology 22(8):1736–1747
Department of Health. National Clinical Guideline—Diagnosis, staging and treatment of patients with breast cancer. National Clinical Guideline No. 7. 2015.
Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784
Aebi S et al (2014) Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 15(2):156–163
Finn RS et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35
Hortobagyi GN et al (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 375(18):1738–1748
Runowicz CD et al (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34(6):611–635
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Wöckel hat Vortrags- und Beraterhonorare von Novartis, Amgen, Pfizer, Roche, Tesaro, Eisai, Aurikamed, Celgene, Riemser erhalten. T. Stüber gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
B. Seelbach-Göbel, Regensburg
U. Wagner, Marburg
Eine Liste der Leitlinienautoren für die gesamte Leitlinienkommission finden Sie in Tab. 2, 3 und 4.
Teile dieses Beitrags finden sich in der Langversion der Leitlinie.
Die gesamte Leitlinie findet sich als Langfassung, Kurzfassung und Methodenreport unter www.leitlinienprogramm-onkologie.de.
Rights and permissions
About this article
Cite this article
Wöckel, A., Stüber, T. Mammakarzinom: Was bringt die S3-Leitlinienaktualisierung Neues?. Gynäkologe 51, 807–815 (2018). https://doi.org/10.1007/s00129-018-4316-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00129-018-4316-3